Anne-Laure Marchal

Anne-Laure Marchal

Auto-generated profile, based on publicly available information

Anne-Laure Marchal

Novartis Institutes for BioMedical Research, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Cancer Discovery
Verified
Journal Article
Open access
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, is manufactured using a next-generation platform in <2 days. Here, we report the preclinical development and preliminary clinical data of YTB323 in adults with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL; NCT03960840). In preclinical mouse models, YTB323 exhibited enhanced in vivo expansion and antitumor activity at lower doses than traditionally manufactured CAR T cells. Clinically, at doses 25-fold lower than tisagenlecleucel, YTB323 showed (i) promising overall safety [cytokine release syndrome (any grade, 35%; grade ≥3, 6%), neurotoxicity (any grade, 25%; grade ≥3, 6%)]; (ii) overall response rates of 75% and 80% for DL1 and DL2, respectively; (iii) comparable CAR T-cell expansion; and (iv) preservation of T-cell phenotype. Current data support the continued development of YTB323 for r/r DLBCL. Significance: Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR as tisagenlecleucel, can be manufactured in <2 days while retaining T-cell stemness and enhancing clinical activity at a 25-fold lower dose. See related commentary by Wang, p. 1961. This article is featured in Selected Articles from This Issue, p. 1949

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
JWJincheng Wu
Jincheng Wu
SCShuqi Chen
Shuqi Chen
GBGuillaume Baneyx
Guillaume Baneyx
AMAnne-Laure Marchal
Anne-Laure Marchal
DQDavid S. Quinn
David S. Quinn
JMJennifer Marie Mataraza
Jennifer Marie Mataraza
Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is a humanized monoclonal antibody against CSF-1. Lacnotuzumab may counteract the tumor suppressive microenvironment induced by CSF-1, potentially enhancing the efficacy of PD-1 inhibition. Methods: MCS110Z2102 is a phase 1b/2 study in cancer patients with advanced malignancies treated by lacnotuzumab combined with the PD-1 inhibitor spartalizumab. Eligible patients with previously treated advanced/metastatic solid tumors received 1, 3, 5, 7.5 and 10 mg/kg intravenous doses of lacnotuzumab in dose escalation combined with 100 mg or 300 mg of spartalizumab administered every 3 weeks. Then, the selected recommended phase 2 dose (RP2D, 7.5 mg/kg lacnotuzumab in combination with 300 mg spartalizumab every 3 weeks) was explored in 4 expansion groups of pancreatic cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC) and malignant melanoma. Here, we report flow cytometric, circulating total CSF1 in plasma and gene expression profiling analyses as evidence of on-target pharmacodynamic effects of lacnotuzumab + spartalizumab in treated patients. Results: The combination of lacnotuzumab and spartalizumab increased the levels of circulating total CSF-1 in plasma, thereby suggesting target engagement and selectively decreased peripheral CSF-1R-expressing intermediate and nonclassical monocytes, at all doses tested. Gene expression profiling by RNA-sequencing in paired biopsies showed down-regulation of macrophage associated genes in patients treated with lacnotuzumab + spartalizumab. In addition, the upregulation of cytotoxic T cell gene signatures was observed. A limited antitumor activity was observed: 2 pancreatic cancer, 1 TNBC and 2 EC patients had a confirmed partial response over 141 patients treated. Conclusions: Flow cytometric, circulating total CSF1 in plasma and gene expression profiling results demonstrated that targeting CSF-1 with lacnotuzumab in the periphery and tumor microenvironment leads to decrease in monocytes and reduced expression of macrophage associated genes in patients with advanced cancers. Unfortunately, in the heavily pretreated patient populations studied in this trial, only a limited clinical efficacy was demonstrated. Citation Format: Jincheng Wu, Shuqi Chen, Guillaume Baneyx, Anne-Laure Marchal, David S. Quinn, Miguel Martin, Andres Cervantes, Janna Sand-Dejmek, Jennifer Marie Mataraza. On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB061.

31 July 2023
Verified
Other
Open access
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 and CTL*019 for Donor 2 and 3; Supplementary Fig. S2. Differential gene expression of CTL*019 cells versus YTB323 cells (preclinical); Supplementary Fig. S3. Preclinical validation of YTB323; Supplementary Fig. S4. Dose-dependent expansion (Cmax and AUC0-21d) of YTB323 and CTL*019 in NSG mice with NALM6; Supplementary Fig. S5. CD4:CD8 ratio comparison of leukapheresis and cell products of YTB323 and tisagenlecleucel; Supplementary Fig. S6. Stemness and memory differentiation gene signatures are retained or enriched for in YTB323 final product; Supplementary Fig. S7. Differential gene expression of tisagenlecleucel versus YTB323 final product; Supplementary Fig. S8. Naive/TSCM cells and a naive stem-like gene signature correlate with higher expansion and a better response; Supplementary Fig. S9. T-cell subset and checkpoint inhibitor analysis by flow cytometry on PBMCs collected post-YTB323 infusion; Supplementary Fig. S10. Pre-clinical T-cell gating strategies.

31 July 2023
Verified
Other
Open access
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 and CTL*019 for Donor 2 and 3; Supplementary Fig. S2. Differential gene expression of CTL*019 cells versus YTB323 cells (preclinical); Supplementary Fig. S3. Preclinical validation of YTB323; Supplementary Fig. S4. Dose-dependent expansion (Cmax and AUC0-21d) of YTB323 and CTL*019 in NSG mice with NALM6; Supplementary Fig. S5. CD4:CD8 ratio comparison of leukapheresis and cell products of YTB323 and tisagenlecleucel; Supplementary Fig. S6. Stemness and memory differentiation gene signatures are retained or enriched for in YTB323 final product; Supplementary Fig. S7. Differential gene expression of tisagenlecleucel versus YTB323 final product; Supplementary Fig. S8. Naive/TSCM cells and a naive stem-like gene signature correlate with higher expansion and a better response; Supplementary Fig. S9. T-cell subset and checkpoint inhibitor analysis by flow cytometry on PBMCs collected post-YTB323 infusion; Supplementary Fig. S10. Pre-clinical T-cell gating strategies.

31 July 2023
Verified
Other
Open access
PDF file
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary Table S2. Lymphodepleting chemotherapies (safety set); Supplementary Table S3. Cytokine release syndrome following YTB323 infusion; Supplementary Table S4. Neurological adverse reactions following YTB323 infusion; Supplementary Table S5. Summary of cellular kinetic parameters in peripheral blood by flow cytometry for YTB323 at DL1 and DL2; Supplementary Table S6. Summary of cellular kinetic parameters in peripheral blood by flow cytometry and qPCR for YTB323 at DL1 and DL2.

11 December 2025
Verified
Other
Open access
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary Table S2. Lymphodepleting chemotherapies (safety set); Supplementary Table S3. Cytokine release syndrome following YTB323 infusion; Supplementary Table S4. Neurological adverse reactions following YTB323 infusion; Supplementary Table S5. Summary of cellular kinetic parameters in peripheral blood by flow cytometry for YTB323 at DL1 and DL2; Supplementary Table S6. Summary of cellular kinetic parameters in peripheral blood by flow cytometry and qPCR for YTB323 at DL1 and DL2.